Literature DB >> 33481809

Risk stratification for advanced colorectal neoplasia based on the findings of the index and first surveillance colonoscopies.

Munenori Honda1, Hideaki Naoe1, Ryosuke Gushima1, Hideaki Miyamoto1, Masakuni Tateyama1, Kouichi Sakurai2, Yasushi Oda3, Yoshitaka Murakami4, Yasuhito Tanaka1.   

Abstract

Risk stratification by index colonoscopy is well established for first surveillance endoscopy, but whether the previous two colonoscopies affect the subsequent advanced neoplasias has not been established. Therefore, the subsequent risk based on the findings of the index and first surveillance colonoscopies were investigated. This retrospective, cohort study was conducted in two clinics and included participants who had undergone two or more colonoscopies after index colonoscopy. High-risk was defined as advanced adenoma (≥ 1 cm, or tubulovillous or villous histology, or high-grade dysplasia). Based on the findings of the index and first surveillance colonoscopies, patients were classified into four categories: category A (both colonoscopy findings were normal), category B (no high-risk findings both times), category C (one time high-risk finding), and category D (high-risk findings both times). The incidence of subsequent advanced neoplasia was examined in each category. A total of 13,426 subjects were included and surveyed during the study periods. The subjects in category D had the highest risk of advanced neoplasia (27.4%, n = 32/117). The subjects in category A had the lowest risk (4.0%, n = 225/5,583). The hazard ratio for advanced neoplasia of category D compared to category A was 9.90 (95% Confidence interval 6.82-14.35, P<0.001). Classification based on the findings of index and first surveillance colonoscopies more effectively stratifies the risk of subsequent advanced neoplasia, resulting in more proper allocation of colonoscopy resources after two consecutive colonoscopies.

Entities:  

Mesh:

Year:  2021        PMID: 33481809      PMCID: PMC7822265          DOI: 10.1371/journal.pone.0245211

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


  26 in total

1.  Clinical impact of surveillance colonoscopy using magnification without diminutive polyp removal.

Authors:  Yuki Ninomiya; Shiro Oka; Shinji Tanaka; Kazuki Boda; Ken Yamashita; Kyoku Sumimoto; Daiki Hirano; Yuzuru Tamaru; Kenjiro Shigita; Nana Hayashi; Taiji Matsuo; Kazuaki Chayama
Journal:  Dig Endosc       Date:  2017-06-06       Impact factor: 7.559

2.  A model to determine colorectal cancer risk using common genetic susceptibility loci.

Authors:  Li Hsu; Jihyoun Jeon; Hermann Brenner; Stephen B Gruber; Robert E Schoen; Sonja I Berndt; Andrew T Chan; Jenny Chang-Claude; Mengmeng Du; Jian Gong; Tabitha A Harrison; Richard B Hayes; Michael Hoffmeister; Carolyn M Hutter; Yi Lin; Reiko Nishihara; Shuji Ogino; Ross L Prentice; Fredrick R Schumacher; Daniela Seminara; Martha L Slattery; Duncan C Thomas; Mark Thornquist; Polly A Newcomb; John D Potter; Yingye Zheng; Emily White; Ulrike Peters
Journal:  Gastroenterology       Date:  2015-02-13       Impact factor: 22.682

3.  Increased risk of metachronous large serrated polyps in individuals with 5- to 9-mm proximal hyperplastic polyps: data from the New Hampshire Colonoscopy Registry.

Authors:  Joseph C Anderson; Christina M Robinson; Lynn F Butterly
Journal:  Gastrointest Endosc       Date:  2020-04-26       Impact factor: 9.427

4.  Risk of adenomas with high-risk characteristics based on two previous colonoscopy.

Authors:  Kang-Heum Suh; Ja Seol Koo; Jong Jin Hyun; Jungsoon Choi; Jang Soo Han; Seung Young Kim; Sung Woo Jung; Yoon Tae Jeen; Sang Woo Lee; Jai Hyun Choi
Journal:  J Gastroenterol Hepatol       Date:  2014-12       Impact factor: 4.029

5.  Risk of cancer in small and diminutive colorectal polyps.

Authors:  Prasanna L Ponugoti; Oscar W Cummings; Douglas K Rex
Journal:  Dig Liver Dis       Date:  2016-06-28       Impact factor: 4.088

6.  A risk index for advanced neoplasia on the second surveillance colonoscopy in patients with previous adenomatous polyps.

Authors:  Thomas F Imperiale; Ravi Juluri; Eric A Sherer; Elizabeth A Glowinski; Cynthia S Johnson; Michael S Morelli
Journal:  Gastrointest Endosc       Date:  2014-06-02       Impact factor: 9.427

7.  High-Risk Adenomas at Screening Colonoscopy Remain Predictive of Future High-Risk Adenomas Despite an Intervening Negative Colonoscopy.

Authors:  Brian A Sullivan; Thomas S Redding; Elizabeth R Hauser; Ziad F Gellad; Xuejun Qin; Samir Gupta; Douglas J Robertson; David G Weiss; Meghan C O'Leary; Ashton N Madison; Kellie J Sims; Christina D Williams; Julian C Hong; David Lieberman; Dawn Provenzale
Journal:  Am J Gastroenterol       Date:  2020-08       Impact factor: 10.864

8.  Young adults and metachronous neoplasia: risks for future advanced adenomas and large serrated polyps compared with older adults.

Authors:  Joseph C Anderson; Christina M Robinson; Lynn F Butterly
Journal:  Gastrointest Endosc       Date:  2019-11-21       Impact factor: 9.427

9.  British Society of Gastroenterology/Association of Coloproctology of Great Britain and Ireland/Public Health England post-polypectomy and post-colorectal cancer resection surveillance guidelines.

Authors:  Matthew D Rutter; James East; Colin J Rees; Neil Cripps; James Docherty; Sunil Dolwani; Philip V Kaye; Kevin J Monahan; Marco R Novelli; Andrew Plumb; Brian P Saunders; Siwan Thomas-Gibson; Damian J M Tolan; Sophie Whyte; Stewart Bonnington; Alison Scope; Ruth Wong; Barbara Hibbert; John Marsh; Billie Moores; Amanda Cross; Linda Sharp
Journal:  Gut       Date:  2019-11-27       Impact factor: 31.793

10.  Long-term colorectal cancer incidence after adenoma removal and the effects of surveillance on incidence: a multicentre, retrospective, cohort study.

Authors:  Amanda J Cross; Emma C Robbins; Kevin Pack; Iain Stenson; Paula L Kirby; Bhavita Patel; Matthew D Rutter; Andrew M Veitch; Brian P Saunders; Stephen W Duffy; Kate Wooldrage
Journal:  Gut       Date:  2020-01-17       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.